Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis
Abstract
Background:
Brain atrophy is a known marker of irreversible tissue damage in multiple sclerosis (MS). Cerebrospinal fluid (CSF) osteopontin (OPN) and neurofilament light chain (NF-L) have been proposed as candidate surrogate markers of inflammatory and neurodegenerative processes in MS.
Objective:
To evaluate the relationship between CSF NF-L and OPN levels and brain grey and white matter volumes in patients with clinically isolated syndrome (CIS) suggestive of MS.
Methods:
A total of 41 CIS patients and 30 neurological controls (NCs) were included. CSF NF-L and OPN were measured by commercial ELISA. Measures of brain volume (normalized brain volume (NBV), normalized grey matter volume (NGV), peripheral grey matter volume (PGV), normalized white matter volume (WMV), and ventricular volume) were obtained by SIENAX. Corpus callosum index (CCI) was calculated. Brain volumes were categorized into ‘high’ and ‘low’ according to the median value.
Results:
CSF NF-L and OPN levels were higher in CIS patients in comparison with NCs. CIS patients with ‘low’ TGV, PGV, and TBV showed higher CSF NF-L levels than CIS patients with ‘high’ brain volumes. TGV and PGV correlated inversely with NF-L levels, whereas CCI was inversely related to OPN levels. CSF NF-L was the only independent predictor of TGV and PGV.
Conclusion:
CSF NF-L tracks mainly grey matter damage in patients with CIS suggestive of MS.
Get full access to this article
View all access and purchase options for this article.
References
1. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 2003; 60: 1157–1162.
2. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101–1107.
3. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77: 257–263.
4. Pérez-Miralles F, Sastre-Garriga J, Tintoré M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013; 19: 1878–1886.
5. Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability. Mult Scler 2011; 17: 1098–1106.
6. Uher T, Benedict RH, Horakova D, et al. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. J Neurol Sci 2014; 347: 229–234.
7. Filippi M, Preziosa P, Copetti M, et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 2013; 81: 1759–1767.
8. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008; 65: 232–235.
9. Bornsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2010; 17: 32–42.
10. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860–864.
11. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206–1213.
12. Fialova L, Bartos A, Svarcova J, et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolate syndrome suggestive of multiple sclerosis. J Neuroimmunol 2013; 262: 113–120.
13. Khalil M, Enzinger C, LangKammer C, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19(4): 436–442.
14. Tortorella C, Direnzo V, Taurisano P, et al. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. Mult Scler 2015; 21: 396–401.
15. Mañé Martínez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015; 21: 550–561.
16. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.
17. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639–1643.
18. Iaffaldano P, Ruggieri M, Viterbo RG, et al. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain Behav Immun 2014; 35: 176–181.
19. Eikelenboom MJ, Petzold A, Lazeron RHC, et al. Multiple Sclerosis: Neurofilament Light Chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219–223.
20. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005(58): 840–846.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
22. Polman CH, Reingold SDC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
23. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.2002.
24. Figueira F, Santos VS, Silva FC, et al. Corpus callosum index: A practical measure for long term follow-up in multiple sclerosis. Arq Neuropsiquiatr 2007; 65: 931–935.
25. Figueira F, Santos VS, Silva FC. A cognitive imaging correlate in multiple sclerosis. Rev Chil Neuropsiquiatr 2003; 41: 86–87.
26. Witelson SF. Hand and sex differences in the isthmus and genu of the human corpus callosum: A postmortem morphological study. Brain 1989; 112: 799–835.
27. Hofer S, Frahma J. Topography of the human corpus callosum revisited: Comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage 2006; 32: 989–994.
28. Granberg T, Bergendal G, Shams S, et al. MRI-defined corpus callosal atrophy in Multiple Sclerosis: A comparison of volumetric measurements, corpus callosum area and index. J Neuroimaging 2015; 25(6): 996–1001.
29. Arrambide G, Espejo C, Eixarch H, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016; 87: 1076–1084.
30. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75: 116–126.
Supplementary Material
Files in Data Supplement
File (msj711774_supplementary_tables.pdf)
- Download
- 221.39 KB
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: May 24, 2017
Issue published: July 2018
Keywords
PubMed: 28537100
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 526
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 18 view articles Opens in new tab
Crossref: 16
- Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A...
- Biomarkers in autoimmune diseases of the central nervous system
- Demographic and disease‐related factors impact on cerebrospinal fluid ...
- ISGylation is induced in neurons by demyelination driving ISG15-depend...
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis
- Serum NfL levels in the first five years predict 10-year thalamic frac...
- Osteopontin levels are associated with late-time lower regional brain ...
- CSF neurofilament light chain predicts 10-year clinical and radiologic...
- Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic ...
- Current state-of-art of the application of serum neurofilaments in mul...
- Osteopontin exacerbates the progression of experimental autoimmune mya...
- Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspart...
- Neurofilament light chain in the assessment of patients with multiple ...
- Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
- DNA Methylation in Multiple Sclerosis
- Remyelination modulators in multiple sclerosis patients
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
